ID   CHK2_HUMAN              Reviewed;         543 AA.
AC   O96017; A8K3Y9; B7ZBF3; B7ZBF4; B7ZBF5; Q6QA03; Q6QA04; Q6QA05; Q6QA06;
AC   Q6QA07; Q6QA08; Q6QA10; Q6QA11; Q6QA12; Q6QA13; Q9HBS5; Q9HCQ8; Q9UGF0;
AC   Q9UGF1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   12-OCT-2022, entry version 240.
DE   RecName: Full=Serine/threonine-protein kinase Chk2;
DE            EC=2.7.11.1;
DE   AltName: Full=CHK2 checkpoint homolog;
DE   AltName: Full=Cds1 homolog;
DE            Short=Hucds1;
DE            Short=hCds1;
DE   AltName: Full=Checkpoint kinase 2;
GN   Name=CHEK2; Synonyms=CDS1, CHK2, RAD53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN PHOSPHORYLATION OF
RP   CDC25C, AND MUTAGENESIS OF ASP-347.
RX   PubMed=9836640; DOI=10.1126/science.282.5395.1893;
RA   Matsuoka S., Huang M., Elledge S.J.;
RT   "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.";
RL   Science 282:1893-1897(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN MITOSIS.
RX   PubMed=9889122; DOI=10.1016/s0960-9822(99)80041-4;
RA   Blasina A., van de Weyer I., Laus M.C., Luyten W.H.M.L., Parker A.E.,
RA   McGowan C.H.;
RT   "A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25
RT   phosphatase.";
RL   Curr. Biol. 9:1-10(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION IN PHOSPHORYLATION OF
RP   CDC25C.
RX   PubMed=10097108; DOI=10.1073/pnas.96.7.3745;
RA   Brown A.L., Lee C.-H., Schwarz J.K., Mitiku N., Piwnica-Worms H.,
RA   Chung J.H.;
RT   "A human Cds1-related kinase that functions downstream of ATM protein in
RT   the cellular response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3745-3750(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 AND
RP   12), AND SUBCELLULAR LOCATION.
RC   TISSUE=Mammary gland;
RX   PubMed=15361853; DOI=10.1038/sj.onc.1207928;
RA   Staalesen V., Falck J., Geisler S., Bartkova J., Boerresen-Dale A.-L.,
RA   Lukas J., Lillehaug J.R., Bartek J., Lonning P.E.;
RT   "Alternative splicing and mutation status of CHEK2 in stage III breast
RT   cancer.";
RL   Oncogene 23:8535-8544(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 9).
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Colon carcinoma;
RA   Shao R.-G., Zhang H., Yu Q., Pommier Y.;
RT   "Chk2/HuCds1 cell cycle checkpoint protein kinase from human colon
RT   carcinoma HT29 cells: regulation by autophosphorylation and DNA-dependent
RT   protein kinase and inhibition by cell cycle regulatory drugs.";
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 12).
RC   TISSUE=T-cell;
RA   Ogawa A., Okabe-Nakamura A.;
RT   "An alternative spliced Chk2.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 13).
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-85; THR-157; MET-436;
RP   LYS-446; ILE-447; SER-448; LYS-501 AND VAL-512.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M., Clamp M.,
RA   Smink L.J., Ainscough R., Almeida J.P., Babbage A.K., Bagguley C.,
RA   Bailey J., Barlow K.F., Bates K.N., Beasley O.P., Bird C.P., Blakey S.E.,
RA   Bridgeman A.M., Buck D., Burgess J., Burrill W.D., Burton J., Carder C.,
RA   Carter N.P., Chen Y., Clark G., Clegg S.M., Cobley V.E., Cole C.G.,
RA   Collier R.E., Connor R., Conroy D., Corby N.R., Coville G.J., Cox A.V.,
RA   Davis J., Dawson E., Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M.,
RA   Ellington A.G., Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S., Hunt S.E.,
RA   Jones M.C., Kershaw J., Kimberley A.M., King A., Laird G.K., Langford C.F.,
RA   Leversha M.A., Lloyd C., Lloyd D.M., Martyn I.D., Mashreghi-Mohammadi M.,
RA   Matthews L.H., Mccann O.T., Mcclay J., Mclaren S., McMurray A.A.,
RA   Milne S.A., Mortimore B.J., Odell C.N., Pavitt R., Pearce A.V., Pearson D.,
RA   Phillimore B.J.C.T., Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y.,
RA   Rogers L., Ross M.T., Scott C.E., Sehra H.K., Skuce C.D., Smalley S.,
RA   Smith M.L., Soderlund C., Spragon L., Steward C.A., Sulston J.E.,
RA   Swann R.M., Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J., Shintani A.,
RA   Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S., Roe B.A., Chen F., Chu L.,
RA   Crabtree J., Deschamps S., Do A., Do T., Dorman A., Fang F., Fu Y., Hu P.,
RA   Hua A., Kenton S., Lai H., Lao H.I., Lewis J., Lewis S., Lin S.-P., Loh P.,
RA   Malaj E., Nguyen T., Pan H., Phan S., Qi S., Qian Y., Ray L., Ren Q.,
RA   Shaull S., Sloan D., Song L., Wang Q., Wang Y., Wang Z., White J.,
RA   Willingham D., Wu H., Yao Z., Zhan M., Zhang G., Chissoe S., Murray J.,
RA   Miller N., Minx P., Fulton R., Johnson D., Bemis G., Bentley D.,
RA   Bradshaw H., Bourne S., Cordes M., Du Z., Fulton L., Goela D., Graves T.,
RA   Hawkins J., Hinds K., Kemp K., Latreille P., Layman D., Ozersky P.,
RA   Rohlfing T., Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K.,
RA   Nelson J., Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,
RA   McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelmann L., Kim U.J.,
RA   Shizuya H., Simon M.I., Dumanski J.P., Peyrard M., Kedra D., Seroussi E.,
RA   Fransson I., Tapia I., Bruder C.E., O'Brien K.P., Wilkinson P.,
RA   Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L., Tilahun Y.,
RA   Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF BRCA1, AND INTERACTION WITH BRCA1.
RX   PubMed=10724175; DOI=10.1038/35004614;
RA   Lee J.S., Collins K.M., Brown A.L., Lee C.H., Chung J.H.;
RT   "hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage
RT   response.";
RL   Nature 404:201-204(2000).
RN   [15]
RP   PHOSPHORYLATION AT THR-68 BY ATM.
RX   PubMed=10973490; DOI=10.1073/pnas.190030497;
RA   Matsuoka S., Rotman G., Ogawa A., Shiloh Y., Tamai K., Elledge S.J.;
RT   "Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:10389-10394(2000).
RN   [16]
RP   PHOSPHORYLATION AT THR-383 AND THR-387, AND MUTAGENESIS OF THR-383 AND
RP   THR-387.
RX   PubMed=11390408; DOI=10.1074/jbc.m104414200;
RA   Lee C.H., Chung J.H.;
RT   "The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation
RT   events on hCds1 that is induced by ionizing radiation.";
RL   J. Biol. Chem. 276:30537-30541(2001).
RN   [17]
RP   FUNCTION IN INTRA S-PHASE CHECKPOINT, FUNCTION IN PHOSPHORYLATION OF
RP   CDC25A, INTERACTION WITH CDC25A, MUTAGENESIS OF ASP-347, CHARACTERIZATION
RP   OF VARIANT COLON CANCER TRP-145, AND CHARACTERIZATION OF VARIANT THR-157.
RX   PubMed=11298456; DOI=10.1038/35071124;
RA   Falck J., Mailand N., Syljuaasen R.G., Bartek J., Lukas J.;
RT   "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA
RT   synthesis.";
RL   Nature 410:842-847(2001).
RN   [18]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO BC.
RX   PubMed=12094328; DOI=10.1086/341943;
RA   Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S.,
RA   Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P.,
RA   Holli K., Blomqvist C., Bartek J., Kallioniemi O.P., Nevanlinna H.;
RT   "A CHEK2 genetic variant contributing to a substantial fraction of familial
RT   breast cancer.";
RL   Am. J. Hum. Genet. 71:432-438(2002).
RN   [19]
RP   HOMODIMERIZATION, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF THR-68.
RX   PubMed=11901158; DOI=10.1074/jbc.m200822200;
RA   Ahn J.Y., Li X., Davis H.L., Canman C.E.;
RT   "Phosphorylation of threonine 68 promotes oligomerization and
RT   autophosphorylation of the Chk2 protein kinase via the forkhead-associated
RT   domain.";
RL   J. Biol. Chem. 277:19389-19395(2002).
RN   [20]
RP   FUNCTION IN APOPTOSIS, FUNCTION IN PHOSPHORYLATION OF PML, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12402044; DOI=10.1038/ncb869;
RA   Yang S., Kuo C., Bisi J.E., Kim M.K.;
RT   "PML-dependent apoptosis after DNA damage is regulated by the checkpoint
RT   kinase hCds1/Chk2.";
RL   Nat. Cell Biol. 4:865-870(2002).
RN   [21]
RP   INTERACTION WITH TP53BP1.
RX   PubMed=12364621; DOI=10.1126/science.1076182;
RA   Wang B., Matsuoka S., Carpenter P.B., Elledge S.J.;
RT   "53BP1, a mediator of the DNA damage checkpoint.";
RL   Science 298:1435-1438(2002).
RN   [22]
RP   FUNCTION, INTERACTION WITH PML AND TP53, AND SUBCELLULAR LOCATION.
RX   PubMed=12810724; DOI=10.1074/jbc.m301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [23]
RP   FUNCTION IN TRANSCRIPTION REGULATION, FUNCTION IN APOPTOSIS, AND FUNCTION
RP   IN PHOSPHORYLATION OF E2F1.
RX   PubMed=12717439; DOI=10.1038/ncb974;
RA   Stevens C., Smith L., La Thangue N.B.;
RT   "Chk2 activates E2F-1 in response to DNA damage.";
RL   Nat. Cell Biol. 5:401-409(2003).
RN   [24]
RP   FUNCTION IN DNA DAMAGE RESPONSE, AND INTERACTION WITH MDC1.
RX   PubMed=12607004; DOI=10.1038/nature01447;
RA   Lou Z., Minter-Dykhouse K., Wu X., Chen J.;
RT   "MDC1 is coupled to activated CHK2 in mammalian DNA damage response
RT   pathways.";
RL   Nature 421:957-961(2003).
RN   [25]
RP   REVIEW ON PHOSPHORYLATION OF TP53 AND OTHER SUBSTRATES.
RX   PubMed=15279791; DOI=10.1016/j.dnarep.2004.03.033;
RA   Ahn J., Urist M., Prives C.;
RT   "The Chk2 protein kinase.";
RL   DNA Repair 3:1039-1047(2004).
RN   [26]
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-68 BY MAP3K20, AND MUTAGENESIS
RP   OF THR-68 AND ASP-368.
RX   PubMed=15342622; DOI=10.1074/jbc.m409961200;
RA   Tosti E., Waldbaum L., Warshaw G., Gross E.A., Ruggieri R.;
RT   "The stress kinase MRK contributes to regulation of DNA damage checkpoints
RT   through a p38gamma-independent pathway.";
RL   J. Biol. Chem. 279:47652-47660(2004).
RN   [27]
RP   FUNCTION IN TP53 ACTIVATION, AND FUNCTION IN PHOSPHORYLATION OF MDM4.
RX   PubMed=16163388; DOI=10.1038/sj.emboj.7600812;
RA   Chen L., Gilkes D.M., Pan Y., Lane W.S., Chen J.;
RT   "ATM and Chk2-dependent phosphorylation of MDMX contribute to p53
RT   activation after DNA damage.";
RL   EMBO J. 24:3411-3422(2005).
RN   [28]
RP   PHOSPHORYLATION AT THR-68, AND DEPHOSPHORYLATION AT THR-68 BY PPM1D.
RX   PubMed=16311512; DOI=10.1038/sj.cdd.4401801;
RA   Fujimoto H., Onishi N., Kato N., Takekawa M., Xu X.Z., Kosugi A., Kondo T.,
RA   Imamura M., Oishi I., Yoda A., Minami Y.;
RT   "Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1
RT   phosphatase.";
RL   Cell Death Differ. 13:1170-1180(2006).
RN   [29]
RP   PHOSPHORYLATION AT SER-62; THR-68 AND SER-73, AND MUTAGENESIS OF SER-73.
RX   PubMed=16481012; DOI=10.1016/j.mrfmmm.2005.12.002;
RA   Bahassi el M., Myer D.L., McKenney R.J., Hennigan R.F., Stambrook P.J.;
RT   "Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its
RT   full activation by ATM and a downstream checkpoint in response to DNA
RT   damage.";
RL   Mutat. Res. 596:166-176(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF RB1.
RX   PubMed=17380128; DOI=10.1038/sj.emboj.7601652;
RA   Inoue Y., Kitagawa M., Taya Y.;
RT   "Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB
RT   and E2F-1 after DNA damage.";
RL   EMBO J. 26:2083-2093(2007).
RN   [31]
RP   FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-456, UBIQUITINATION, AND
RP   MUTAGENESIS OF SER-456.
RX   PubMed=17715138; DOI=10.1074/jbc.m704642200;
RA   Kass E.M., Ahn J., Tanaka T., Freed-Pastor W.A., Keezer S., Prives C.;
RT   "Stability of checkpoint kinase 2 is regulated via phosphorylation at
RT   serine 456.";
RL   J. Biol. Chem. 282:30311-30321(2007).
RN   [32]
RP   FUNCTION IN DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF FOXM1.
RX   PubMed=17101782; DOI=10.1128/mcb.01068-06;
RA   Tan Y., Raychaudhuri P., Costa R.H.;
RT   "Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate
RT   expression of DNA repair genes.";
RL   Mol. Cell. Biol. 27:1007-1016(2007).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF NEK6.
RX   PubMed=18728393; DOI=10.4161/cc.7.17.6551;
RA   Lee M.Y., Kim H.J., Kim M.A., Jee H.J., Kim A.J., Bae Y.S., Park J.I.,
RA   Chung J.H., Yun J.;
RT   "Nek6 is involved in G2/M phase cell cycle arrest through DNA damage-
RT   induced phosphorylation.";
RL   Cell Cycle 7:2705-2709(2008).
RN   [34]
RP   FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-379, MUTAGENESIS OF SER-379,
RP   UBIQUITINATION, AND INTERACTION WITH CUL1.
RX   PubMed=18644861; DOI=10.1128/mcb.00821-08;
RA   Lovly C.M., Yan L., Ryan C.E., Takada S., Piwnica-Worms H.;
RT   "Regulation of Chk2 ubiquitination and signaling through
RT   autophosphorylation of serine 379.";
RL   Mol. Cell. Biol. 28:5874-5885(2008).
RN   [35]
RP   FUNCTION IN RAD51-MEDIATED DNA REPAIR, AND FUNCTION IN PHOSPHORYLATION OF
RP   BRCA2.
RX   PubMed=18317453; DOI=10.1038/onc.2008.17;
RA   Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E.,
RA   Stambrook P.J.;
RT   "The checkpoint kinases Chk1 and Chk2 regulate the functional associations
RT   between hBRCA2 and Rad51 in response to DNA damage.";
RL   Oncogene 27:3977-3985(2008).
RN   [36]
RP   PHOSPHORYLATION BY PLK4.
RX   PubMed=19164942; DOI=10.4161/cc.8.2.7355;
RA   Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.;
RT   "Polo-like kinase 4 phosphorylates Chk2.";
RL   Cell Cycle 8:327-329(2009).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF BRCA1, AND FUNCTION IN CHROMOSOMAL
RP   STABILITY.
RX   PubMed=20364141; DOI=10.1038/ncb2051;
RA   Stolz A., Ertych N., Kienitz A., Vogel C., Schneider V., Fritz B.,
RA   Jacob R., Dittmar G., Weichert W., Petersen I., Bastians H.;
RT   "The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in
RT   human somatic cells.";
RL   Nat. Cell Biol. 12:492-499(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO BC, VARIANTS CYS-180 AND TYR-371, AND
RP   CHARACTERIZATION OF VARIANT TYR-371.
RX   PubMed=21618645; DOI=10.1002/humu.21538;
RA   Liu Y., Liao J., Xu Y., Chen W., Liu D., Ouyang T., Li J., Wang T., Fan Z.,
RA   Fan T., Lin B., Xu X., Xie Y.;
RT   "A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk
RT   in Chinese women.";
RL   Hum. Mutat. 32:1000-1003(2011).
RN   [40]
RP   UBIQUITINATION BY RNF8.
RX   PubMed=22266820; DOI=10.1038/nsmb.2211;
RA   Feng L., Chen J.;
RT   "The E3 ligase RNF8 regulates KU80 removal and NHEJ repair.";
RL   Nat. Struct. Mol. Biol. 19:201-206(2012).
RN   [41]
RP   FUNCTION, AND INTERACTION WITH CCAR2 AND SIRT1.
RX   PubMed=25361978; DOI=10.1093/nar/gku1065;
RA   Magni M., Ruscica V., Buscemi G., Kim J.E., Nachimuthu B.T., Fontanella E.,
RA   Delia D., Zannini L.;
RT   "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced
RT   apoptosis.";
RL   Nucleic Acids Res. 42:13150-13160(2014).
RN   [42]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32001251; DOI=10.1016/j.jmb.2020.01.021;
RA   Hembram D.S.S., Negi H., Biswas P., Tripathi V., Bhushan L., Shet D.,
RA   Kumar V., Das R.;
RT   "The Viral SUMO-Targeted Ubiquitin Ligase ICP0 is Phosphorylated and
RT   Activated by Host Kinase Chk2.";
RL   J. Mol. Biol. 432:1952-1977(2020).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 64-212.
RX   PubMed=12049740; DOI=10.1016/s1097-2765(02)00527-0;
RA   Li J., Williams B.L., Haire L.F., Goldberg M., Wilker E., Durocher D.,
RA   Yaffe M.B., Jackson S.P., Smerdon S.J.;
RT   "Structural and functional versatility of the FHA domain in DNA-damage
RT   signaling by the tumor suppressor kinase Chk2.";
RL   Mol. Cell 9:1045-1054(2002).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 210-531 IN COMPLEX WITH ADP AND
RP   INHIBITOR, HOMODIMERIZATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=16794575; DOI=10.1038/sj.emboj.7601209;
RA   Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D.,
RA   Mittnacht S., Pearl L.H.;
RT   "Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-
RT   loop exchange.";
RL   EMBO J. 25:3179-3190(2006).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 84-502 OF HOMODIMER.
RX   PubMed=19782031; DOI=10.1016/j.molcel.2009.09.007;
RA   Cai Z., Chehab N.H., Pavletich N.P.;
RT   "Structure and activation mechanism of the CHK2 DNA damage checkpoint
RT   kinase.";
RL   Mol. Cell 35:818-829(2009).
RN   [46]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=24825908; DOI=10.1074/jbc.m114.547208;
RA   Cheung C.T., Singh R., Kalra R.S., Kaul S.C., Wadhwa R.;
RT   "Collaborator of ARF (CARF) regulates proliferative fate of human cells by
RT   dose-dependent regulation of DNA damage signaling.";
RL   J. Biol. Chem. 289:18258-18269(2014).
RN   [47]
RP   VARIANT THR-157, AND VARIANT COLON CANCER TRP-145.
RX   PubMed=10617473; DOI=10.1126/science.286.5449.2528;
RA   Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C.R.,
RA   Shannon K.E., Lubratovich M., Versalis S.J., Isselbacher K.J.,
RA   Fraumeni J.F. Jr., Birch J.M., Li F.P., Garber J.E., Haber D.A.;
RT   "Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.";
RL   Science 286:2528-2531(1999).
RN   [48]
RP   VARIANT THR-157.
RX   PubMed=11461078; DOI=10.1054/bjoc.2001.1858;
RA   Allinen M., Huusko P., Maentyniemi S., Launonen V., Winqvist R.;
RT   "Mutation analysis of the CHK2 gene in families with hereditary breast
RT   cancer.";
RL   Br. J. Cancer 85:209-212(2001).
RN   [49]
RP   VARIANT LFS2 TRP-145.
RX   PubMed=11719428;
RA   Lee S.B., Kim S.H., Bell D.W., Wahrer D.C.R., Schiripo T.A., Jorczak M.M.,
RA   Sgroi D.C., Garber J.E., Li F.P., Nichols K.E., Varley J.M., Godwin A.K.,
RA   Shannon K.M., Harlow E., Haber D.A.;
RT   "Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni
RT   Syndrome.";
RL   Cancer Res. 61:8062-8067(2001).
RN   [50]
RP   VARIANT MULTIPLE CANCERS LYS-59.
RX   PubMed=12052256; DOI=10.1186/bcr435;
RA   Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Hafsteinsdottir S.H.,
RA   Ragnarsson G., Barkardottir R.B., Arason A., Egilsson V.,
RA   Bergthorsson J.T.;
RT   "Mutation analysis of the CHK2 gene in breast carcinoma and other
RT   cancers.";
RL   Breast Cancer Res. 4:R4-R4(2002).
RN   [51]
RP   VARIANT BC GLY-117, AND VARIANTS GLN-137 AND HIS-180.
RX   PubMed=12454775; DOI=10.1038/sj.bjc.6600637;
RA   Sodha N., Bullock S., Taylor R., Mitchell G., Guertl-Lackner B.,
RA   Williams R.D., Bevan S., Bishop K., McGuire S., Houlston R.S., Eeles R.A.;
RT   "CHEK2 variants in susceptibility to breast cancer and evidence of
RT   retention of the wild type allele in tumours.";
RL   Br. J. Cancer 87:1445-1448(2002).
RN   [52]
RP   VARIANTS OSTEOSARCOMA SER-17 AND LEU-85.
RX   PubMed=11746983; DOI=10.1002/gcc.1207;
RA   Miller C.W., Ikezoe T., Krug U., Hofmann W.K., Tavor S., Vegesna V.,
RA   Tsukasaki K., Takeuchi S., Koeffler H.P.;
RT   "Mutations of the CHK2 gene are found in some osteosarcomas, but are rare
RT   in breast, lung, and ovarian tumors.";
RL   Genes Chromosomes Cancer 33:17-21(2002).
RN   [53]
RP   VARIANTS PROSTATE CANCER LYS-64; PRO-145; ARG-167; CYS-180; HIS-180;
RP   CYS-181; HIS-181; LYS-239; PHE-251; HIS-318; PRO-323; CYS-327 AND LYS-476,
RP   AND VARIANT THR-157.
RX   PubMed=12533788; DOI=10.1086/346094;
RA   Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K.,
RA   Qian C., Marks A.F., Slager S.L., Peterson B.J., Smith D.I., Cheville J.C.,
RA   Blute M.L., Jacobsen S.J., Schaid D.J., Tindall D.J., Thibodeau S.N.,
RA   Liu W.;
RT   "Mutations in CHEK2 associated with prostate cancer risk.";
RL   Am. J. Hum. Genet. 72:270-280(2003).
RN   [54]
RP   VARIANT BC GLY-117, AND VARIANTS TRP-145 AND THR-157.
RX   PubMed=12610780; DOI=10.1086/373965;
RA   Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M.,
RA   Evans D.G., Eccles D., Meijers C., Lohman F., Klijn J.,
RA   van den Ouweland A., Brady A., Cole T., Collins A., Cox H., Donaldson A.,
RA   Eeles R., Evans G., Gregory H., Gray J., Houlston R., Lalloo F.,
RA   Lucassen A., Mackay J., Mitchell G., Morrison P., Murday V., Narod S.,
RA   Patterson J., Peretz T., Phelan C.M., Rogers M., Schofield A., Tonin P.,
RA   Weber B., Weber W., Futreal P.A., Nathanson K.L., Weber B.L., Easton D.F.,
RA   Stratton M.R., Rahman N.;
RT   "Variants in CHEK2 other than 1100delC do not make a major contribution to
RT   breast cancer susceptibility.";
RL   Am. J. Hum. Genet. 72:1023-1028(2003).
RN   [55]
RP   VARIANT THR-157.
RX   PubMed=14612911; DOI=10.1038/sj.bjc.6601425;
RA   Seppaelae E.H., Ikonen T., Mononen N., Autio V., Roekman A.,
RA   Matikainen M.P., Tammela T.L.J., Schleutker J.;
RT   "CHEK2 variants associate with hereditary prostate cancer.";
RL   Br. J. Cancer 89:1966-1970(2003).
RN   [56]
RP   VARIANT THR-157.
RX   PubMed=15492928; DOI=10.1086/426403;
RA   Cybulski C., Gorski B., Huzarski T., Masojc B., Mierzejewski M.,
RA   Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J.,
RA   Zlowocka E., Lenner M., Grabowska E., Nej K., Castaneda J., Medrek K.,
RA   Szymanska A., Szymanska J., Kurzawski G., Suchy J., Oszurek O., Witek A.,
RA   Narod S.A., Lubinski J.;
RT   "CHEK2 is a multiorgan cancer susceptibility gene.";
RL   Am. J. Hum. Genet. 75:1131-1135(2004).
RN   [57]
RP   VARIANTS TRP-145 AND THR-157.
RX   PubMed=15535844; DOI=10.1186/bcr933;
RA   Friedrichsen D.M., Malone K.E., Doody D.R., Daling J.R., Ostrander E.A.;
RT   "Frequency of CHEK2 mutations in a population based, case-control study of
RT   breast cancer in young women.";
RL   Breast Cancer Res. 6:R629-R635(2004).
RN   [58]
RP   VARIANT THR-157.
RX   PubMed=15087378; DOI=10.1158/0008-5472.can-04-0341;
RA   Cybulski C., Huzarski T., Gorski B., Masojc B., Mierzejewski M.,
RA   Debniak T., Gliniewicz B., Matyjasik J., Zlowocka E., Kurzawski G.,
RA   Sikorski A., Posmyk M., Szwiec M., Czajka R., Narod S.A., Lubinski J.;
RT   "A novel founder CHEK2 mutation is associated with increased prostate
RT   cancer risk.";
RL   Cancer Res. 64:2677-2679(2004).
RN   [59]
RP   VARIANT THR-157.
RX   PubMed=15095295; DOI=10.1002/ijc.20073;
RA   Dufault M.R., Betz B., Wappenschmidt B., Hofmann W., Bandick K., Golla A.,
RA   Pietschmann A., Nestle-Kraemling C., Rhiem K., Huettner C., von Lindern C.,
RA   Dall P., Kiechle M., Untch M., Jonat W., Meindl A., Scherneck S.,
RA   Niederacher D., Schmutzler R.K., Arnold N.;
RT   "Limited relevance of the CHEK2 gene in hereditary breast cancer.";
RL   Int. J. Cancer 110:320-325(2004).
RN   [60]
RP   VARIANT THR-157.
RX   PubMed=15239132; DOI=10.1002/ijc.20299;
RA   Kilpivaara O., Vahteristo P., Falck J., Syrjaekoski K., Eerola H.,
RA   Easton D., Bartkova J., Lukas J., Heikkilae P., Aittomaeki K., Holli K.,
RA   Blomqvist C., Kallioniemi O.-P., Bartek J., Nevanlinna H.;
RT   "CHEK2 variant I157T may be associated with increased breast cancer risk.";
RL   Int. J. Cancer 111:543-547(2004).
RN   [61]
RP   VARIANTS LEU-85 AND PHE-428.
RX   PubMed=15649950; DOI=10.1093/hmg/ddi052;
RA   Shaag A., Walsh T., Renbaum P., Kirchhoff T., Nafa K., Shiovitz S.,
RA   Mandell J.B., Welcsh P., Lee M.K., Ellis N., Offit K., Levy-Lahad E.,
RA   King M.-C.;
RT   "Functional and genomic approaches reveal an ancient CHEK2 allele
RT   associated with breast cancer in the Ashkenazi Jewish population.";
RL   Hum. Mol. Genet. 14:555-563(2005).
RN   [62]
RP   VARIANT THR-157.
RX   PubMed=15810020; DOI=10.1002/ijc.21022;
RA   Bogdanova N., Enbetaen-Dubrowinskaja N., Feshchenko S., Lazjuk G.I.,
RA   Rogov Y.I., Dammann O., Bremer M., Karstens J.H., Sohn C., Doerk T.;
RT   "Association of two mutations in the CHEK2 gene with breast cancer.";
RL   Int. J. Cancer 116:263-266(2005).
RN   [63]
RP   VARIANT BC GLY-117, AND VARIANTS GLN-137; TRP-145; THR-157 AND HIS-180.
RX   PubMed=15818573; DOI=10.1002/path.1764;
RA   van Puijenbroek M., van Asperen C.J., van Mil A., Devilee P., van Wezel T.,
RA   Morreau H.;
RT   "Homozygosity for a CHEK2*1100delC mutation identified in familial
RT   colorectal cancer does not lead to a severe clinical phenotype.";
RL   J. Pathol. 206:198-204(2005).
RN   [64]
RP   VARIANT BC CYS-390, CHARACTERIZATION OF VARIANT BC CYS-390, AND FUNCTION.
RX   PubMed=25619829; DOI=10.1038/onc.2014.443;
RA   Wang N., Ding H., Liu C., Li X., Wei L., Yu J., Liu M., Ying M., Gao W.,
RA   Jiang H., Wang Y.;
RT   "A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese
RT   breast cancer patients impairs its activity and is associated with
RT   increased breast cancer risk.";
RL   Oncogene 34:5198-5205(2015).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is required for
CC       checkpoint-mediated cell cycle arrest, activation of DNA repair and
CC       apoptosis in response to the presence of DNA double-strand breaks. May
CC       also negatively regulate cell cycle progression during unperturbed cell
CC       cycles. Following activation, phosphorylates numerous effectors
CC       preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates
CC       cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B
CC       and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase
CC       activity leads to increased inhibitory tyrosine phosphorylation of CDK-
CC       cyclin complexes and blocks cell cycle progression. May also
CC       phosphorylate NEK6 which is involved in G2/M cell cycle arrest.
CC       Regulates DNA repair through phosphorylation of BRCA2, enhancing the
CC       association of RAD51 with chromatin which promotes DNA repair by
CC       homologous recombination. Also stimulates the transcription of genes
CC       involved in DNA repair (including BRCA2) through the phosphorylation
CC       and activation of the transcription factor FOXM1. Regulates apoptosis
CC       through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation
CC       of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2,
CC       leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may
CC       also reduce degradation of p53/TP53. Also controls the transcription of
CC       pro-apoptotic genes through phosphorylation of the transcription factor
CC       E2F1. Tumor suppressor, it may also have a DNA damage-independent
CC       function in mitotic spindle assembly by phosphorylating BRCA1. Its
CC       absence may be a cause of the chromosomal instability observed in some
CC       cancer cells. Promotes the CCAR2-SIRT1 association and is required for
CC       CCAR2-mediated SIRT1 inhibition (PubMed:25361978).
CC       {ECO:0000250|UniProtKB:Q9Z265, ECO:0000269|PubMed:10097108,
CC       ECO:0000269|PubMed:10724175, ECO:0000269|PubMed:11298456,
CC       ECO:0000269|PubMed:12402044, ECO:0000269|PubMed:12607004,
CC       ECO:0000269|PubMed:12717439, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:16163388, ECO:0000269|PubMed:17101782,
CC       ECO:0000269|PubMed:17380128, ECO:0000269|PubMed:17715138,
CC       ECO:0000269|PubMed:18317453, ECO:0000269|PubMed:18644861,
CC       ECO:0000269|PubMed:18728393, ECO:0000269|PubMed:20364141,
CC       ECO:0000269|PubMed:25361978, ECO:0000269|PubMed:25619829,
CC       ECO:0000269|PubMed:9836640, ECO:0000269|PubMed:9889122}.
CC   -!- FUNCTION: (Microbial infection) Phosphorylates herpes simplex virus
CC       1/HHV-1 protein ICP0 and thus activates its SUMO-targeted ubiquitin
CC       ligase activity. {ECO:0000269|PubMed:32001251}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated through phosphorylation at Thr-68 by ATM
CC       in response to DNA double-strand breaks. Activation is modulated by
CC       several mediators including MDC1 and TP53BP1. Induces homodimerization
CC       with exchange of the T-loop/activation segment between protomers and
CC       transphosphorylation of the protomers. The autophosphorylated kinase
CC       dimer is fully active. Negatively regulated by PPM1D through
CC       dephosphorylation of Thr-68. {ECO:0000269|PubMed:15342622}.
CC   -!- SUBUNIT: Homodimer. Homodimerization is part of the activation process
CC       but the dimer may dissociate following activation. Interacts with PML.
CC       Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts
CC       with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires
CC       ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1;
CC       modulates CHEK2 phosphorylation at Thr-68 in response to ionizing
CC       radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates
CC       its degradation in response to ionizing radiation. Interacts with CUL1;
CC       mediates CHEK2 ubiquitination and regulation. Interacts with CDKN2AIP.
CC       Interacts (via protein kinase domain) with CCAR2 (via N-terminus).
CC       Interacts with SIRT1. {ECO:0000269|PubMed:10724175,
CC       ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12364621,
CC       ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:16794575, ECO:0000269|PubMed:18644861,
CC       ECO:0000269|PubMed:24825908, ECO:0000269|PubMed:25361978}.
CC   -!- INTERACTION:
CC       O96017; Q9NY61: AATF; NbExp=4; IntAct=EBI-1180783, EBI-372428;
CC       O96017; Q9UQ88-1: CDK11A; NbExp=2; IntAct=EBI-1180783, EBI-11579223;
CC       O96017; O96017: CHEK2; NbExp=6; IntAct=EBI-1180783, EBI-1180783;
CC       O96017; Q9Y248: GINS2; NbExp=2; IntAct=EBI-1180783, EBI-747491;
CC       O96017; Q13007: IL24; NbExp=3; IntAct=EBI-1180783, EBI-3915542;
CC       O96017; Q96KN1: LRATD2; NbExp=3; IntAct=EBI-1180783, EBI-9057780;
CC       O96017; P56645: PER3; NbExp=2; IntAct=EBI-1180783, EBI-2827813;
CC       O96017; P53350: PLK1; NbExp=7; IntAct=EBI-1180783, EBI-476768;
CC       O96017; O15355: PPM1G; NbExp=2; IntAct=EBI-1180783, EBI-725702;
CC       O96017; Q15172: PPP2R5A; NbExp=2; IntAct=EBI-1180783, EBI-641666;
CC       O96017; Q15173: PPP2R5B; NbExp=2; IntAct=EBI-1180783, EBI-1369497;
CC       O96017; Q13362-1: PPP2R5C; NbExp=3; IntAct=EBI-1180783, EBI-1266170;
CC       O96017; Q13362-2: PPP2R5C; NbExp=2; IntAct=EBI-1180783, EBI-1266173;
CC       O96017; Q13362-3: PPP2R5C; NbExp=4; IntAct=EBI-1180783, EBI-1266176;
CC       O96017; Q16537: PPP2R5E; NbExp=3; IntAct=EBI-1180783, EBI-968374;
CC       O96017; P06400: RB1; NbExp=3; IntAct=EBI-1180783, EBI-491274;
CC       O96017; Q5VTR2: RNF20; NbExp=3; IntAct=EBI-1180783, EBI-2372238;
CC       O96017; P55072: VCP; NbExp=2; IntAct=EBI-1180783, EBI-355164;
CC       O96017; P18887: XRCC1; NbExp=8; IntAct=EBI-1180783, EBI-947466;
CC       O96017; PRO_0000037319 [P0C6X7]: rep; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-25487926;
CC       O96017; P06725: UL83; Xeno; NbExp=2; IntAct=EBI-1180783, EBI-9545359;
CC       O96017; PRO_0000037577 [P27958]; Xeno; NbExp=3; IntAct=EBI-1180783, EBI-6904388;
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus. Note=Isoform 10 is present
CC       throughout the cell.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 7]: Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 9]: Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 12]: Nucleus.
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body. Nucleus, nucleoplasm.
CC       Note=Recruited into PML bodies together with TP53.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=13;
CC       Name=1;
CC         IsoId=O96017-1; Sequence=Displayed;
CC       Name=2; Synonyms=ins2;
CC         IsoId=O96017-2; Sequence=VSP_014564, VSP_014567, VSP_014568;
CC       Name=3; Synonyms=del2-12;
CC         IsoId=O96017-3; Sequence=VSP_014559;
CC       Name=4; Synonyms=del2-3;
CC         IsoId=O96017-4; Sequence=VSP_014558;
CC       Name=5; Synonyms=del4;
CC         IsoId=O96017-5; Sequence=VSP_014565, VSP_014566;
CC       Name=6; Synonyms=sub3;
CC         IsoId=O96017-6; Sequence=VSP_014562, VSP_014563;
CC       Name=7; Synonyms=del9-12;
CC         IsoId=O96017-7; Sequence=VSP_014572, VSP_014573;
CC       Name=8; Synonyms=del7;
CC         IsoId=O96017-8; Sequence=VSP_014569, VSP_014570;
CC       Name=9; Synonyms=insx;
CC         IsoId=O96017-9; Sequence=VSP_014557;
CC       Name=10; Synonyms=iso2;
CC         IsoId=O96017-10; Sequence=VSP_014560, VSP_014561;
CC       Name=11; Synonyms=iso1;
CC         IsoId=O96017-11; Sequence=VSP_014556;
CC       Name=12; Synonyms=del9;
CC         IsoId=O96017-12; Sequence=VSP_014571;
CC       Name=13;
CC         IsoId=O96017-13; Sequence=VSP_045148;
CC   -!- TISSUE SPECIFICITY: High expression is found in testis, spleen, colon
CC       and peripheral blood leukocytes. Low expression is found in other
CC       tissues.
CC   -!- PTM: Phosphorylated. Phosphorylated at Ser-73 by PLK3 in response to
CC       DNA damage, promoting phosphorylation at Thr-68 by ATM and the G2/M
CC       transition checkpoint. Phosphorylation at Thr-68 induces
CC       homodimerization. Autophosphorylates at Thr-383 and Thr-387 in the T-
CC       loop/activation segment upon dimerization to become fully active and
CC       phosphorylate its substrates like for instance CDC25C. DNA damage-
CC       induced autophosphorylation at Ser-379 induces CUL1-mediated
CC       ubiquitination and regulates the pro-apoptotic function.
CC       Phosphorylation at Ser-456 also regulates ubiquitination.
CC       Phosphorylated by PLK4. {ECO:0000269|PubMed:10973490,
CC       ECO:0000269|PubMed:11390408, ECO:0000269|PubMed:15342622,
CC       ECO:0000269|PubMed:16311512, ECO:0000269|PubMed:16481012,
CC       ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18644861,
CC       ECO:0000269|PubMed:19164942}.
CC   -!- PTM: Ubiquitinated. CUL1-mediated ubiquitination regulates the pro-
CC       apoptotic function. Ubiquitination may also regulate protein stability.
CC       Ubiquitinated by RNF8 via 'Lys-48'-linked ubiquitination.
CC   -!- DISEASE: Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]: A highly penetrant
CC       familial cancer syndrome that in its classic form is defined by the
CC       existence of a proband affected by a sarcoma before 45 years with a
CC       first degree relative affected by any tumor before 45 years and another
CC       first degree relative with any tumor before 45 years or a sarcoma at
CC       any age. Other clinical definitions for LFS have been proposed
CC       (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like
CC       syndrome (LFL). In these families affected relatives develop a diverse
CC       set of malignancies at unusually early ages. Four types of cancers
CC       account for 80% of tumors occurring in TP53 germline mutation carriers:
CC       breast cancers, soft tissue and bone sarcomas, brain tumors
CC       (astrocytomas) and adrenocortical carcinomas. Less frequent tumors
CC       include choroid plexus carcinoma or papilloma before the age of 15,
CC       rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant
CC       phyllodes tumor, colorectal and gastric cancers.
CC       {ECO:0000269|PubMed:11719428}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in
CC       tissues of the prostate. Most prostate cancers are adenocarcinomas that
CC       develop in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of patients
CC       include small cell carcinoma, mucinous carcinoma, prostatic ductal
CC       carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal
CC       cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell
CC       carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:12533788}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating
CC       in bone-forming cells, affecting the ends of long bones. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal carcinoma is
CC       by far the most common type. Breast cancer is etiologically and
CC       genetically heterogeneous. Important genetic factors have been
CC       indicated by familial occurrence and bilateral involvement. Mutations
CC       at more than one locus can be involved in different families or even in
CC       the same case. {ECO:0000269|PubMed:12094328,
CC       ECO:0000269|PubMed:12454775, ECO:0000269|PubMed:12610780,
CC       ECO:0000269|PubMed:15818573, ECO:0000269|PubMed:21618645,
CC       ECO:0000269|PubMed:25619829}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Lacks enzymatic activity. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Lacks enzymatic activity. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Lacks enzymatic activity. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Retains low level of catalytic activity.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Lacks enzymatic activity. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Lacks enzymatic activity. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. CHK2 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CHEK2ID312.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/chek2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF086904; AAC83693.1; -; mRNA.
DR   EMBL; AJ131197; CAA10319.1; -; mRNA.
DR   EMBL; AF096279; AAD11784.1; -; mRNA.
DR   EMBL; AY551295; AAS58456.1; -; mRNA.
DR   EMBL; AY551296; AAS58457.1; -; mRNA.
DR   EMBL; AY551297; AAS58458.1; -; mRNA.
DR   EMBL; AY551298; AAS58459.1; -; mRNA.
DR   EMBL; AY551299; AAS58460.1; -; mRNA.
DR   EMBL; AY551300; AAS58461.1; -; mRNA.
DR   EMBL; AY551301; AAS58462.1; -; mRNA.
DR   EMBL; AY551302; AAS58463.1; -; mRNA.
DR   EMBL; AY551303; AAS58464.1; -; mRNA.
DR   EMBL; AY551304; AAS58465.1; -; mRNA.
DR   EMBL; AY551305; AAS58466.1; -; mRNA.
DR   EMBL; CR456418; CAG30304.1; -; mRNA.
DR   EMBL; AF174135; AAD48504.1; -; mRNA.
DR   EMBL; AB040105; BAB17231.1; -; mRNA.
DR   EMBL; AK290754; BAF83443.1; -; mRNA.
DR   EMBL; AF217975; AAG17218.1; -; mRNA.
DR   EMBL; AY800241; AAV41895.1; -; Genomic_DNA.
DR   EMBL; AL117330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL121825; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471095; EAW59755.1; -; Genomic_DNA.
DR   EMBL; BC004207; AAH04207.1; -; mRNA.
DR   CCDS; CCDS13843.1; -. [O96017-1]
DR   CCDS; CCDS13844.1; -. [O96017-12]
DR   CCDS; CCDS33629.1; -. [O96017-9]
DR   RefSeq; NP_001005735.1; NM_001005735.1. [O96017-9]
DR   RefSeq; NP_001244316.1; NM_001257387.1. [O96017-13]
DR   RefSeq; NP_009125.1; NM_007194.3. [O96017-1]
DR   RefSeq; NP_665861.1; NM_145862.2. [O96017-12]
DR   RefSeq; XP_011528147.1; XM_011529845.2. [O96017-13]
DR   RefSeq; XP_016884050.1; XM_017028561.1. [O96017-13]
DR   PDB; 1GXC; X-ray; 2.70 A; A/D/G/J=64-212.
DR   PDB; 2CN5; X-ray; 2.25 A; A=210-531.
DR   PDB; 2CN8; X-ray; 2.70 A; A=210-531.
DR   PDB; 2W0J; X-ray; 2.05 A; A=210-531.
DR   PDB; 2W7X; X-ray; 2.07 A; A=210-531.
DR   PDB; 2WTC; X-ray; 3.00 A; A=210-531.
DR   PDB; 2WTD; X-ray; 2.75 A; A=210-531.
DR   PDB; 2WTI; X-ray; 2.50 A; A=210-531.
DR   PDB; 2WTJ; X-ray; 2.10 A; A=210-531.
DR   PDB; 2XBJ; X-ray; 2.30 A; A=210-531.
DR   PDB; 2XK9; X-ray; 2.35 A; A=210-531.
DR   PDB; 2XM8; X-ray; 3.40 A; A=210-531.
DR   PDB; 2XM9; X-ray; 2.50 A; A=210-531.
DR   PDB; 2YCF; X-ray; 1.77 A; A=210-530.
DR   PDB; 2YCQ; X-ray; 2.05 A; A=210-531.
DR   PDB; 2YCR; X-ray; 2.20 A; A=210-531.
DR   PDB; 2YCS; X-ray; 2.35 A; A=210-531.
DR   PDB; 2YIQ; X-ray; 1.89 A; A=210-531.
DR   PDB; 2YIR; X-ray; 2.10 A; A=210-531.
DR   PDB; 2YIT; X-ray; 2.20 A; A=210-531.
DR   PDB; 3I6U; X-ray; 3.00 A; A/B=84-502.
DR   PDB; 3I6W; X-ray; 3.25 A; A/B/C/D/E/F/G/H=70-512.
DR   PDB; 3VA4; X-ray; 1.54 A; C=63-73.
DR   PDB; 4A9R; X-ray; 2.85 A; A=210-531.
DR   PDB; 4A9S; X-ray; 2.66 A; A=210-531.
DR   PDB; 4A9T; X-ray; 2.70 A; A=210-531.
DR   PDB; 4A9U; X-ray; 2.48 A; A=210-531.
DR   PDB; 4BDA; X-ray; 2.60 A; A=210-531.
DR   PDB; 4BDB; X-ray; 2.50 A; A=210-531.
DR   PDB; 4BDC; X-ray; 3.00 A; A=210-531.
DR   PDB; 4BDD; X-ray; 2.67 A; A=210-531.
DR   PDB; 4BDE; X-ray; 2.55 A; A=210-531.
DR   PDB; 4BDF; X-ray; 2.70 A; A=210-531.
DR   PDB; 4BDG; X-ray; 2.84 A; A=210-531.
DR   PDB; 4BDH; X-ray; 2.70 A; A=210-531.
DR   PDB; 4BDI; X-ray; 2.32 A; A=210-531.
DR   PDB; 4BDJ; X-ray; 3.01 A; A=210-531.
DR   PDB; 4BDK; X-ray; 3.30 A; A=210-531.
DR   PDBsum; 1GXC; -.
DR   PDBsum; 2CN5; -.
DR   PDBsum; 2CN8; -.
DR   PDBsum; 2W0J; -.
DR   PDBsum; 2W7X; -.
DR   PDBsum; 2WTC; -.
DR   PDBsum; 2WTD; -.
DR   PDBsum; 2WTI; -.
DR   PDBsum; 2WTJ; -.
DR   PDBsum; 2XBJ; -.
DR   PDBsum; 2XK9; -.
DR   PDBsum; 2XM8; -.
DR   PDBsum; 2XM9; -.
DR   PDBsum; 2YCF; -.
DR   PDBsum; 2YCQ; -.
DR   PDBsum; 2YCR; -.
DR   PDBsum; 2YCS; -.
DR   PDBsum; 2YIQ; -.
DR   PDBsum; 2YIR; -.
DR   PDBsum; 2YIT; -.
DR   PDBsum; 3I6U; -.
DR   PDBsum; 3I6W; -.
DR   PDBsum; 3VA4; -.
DR   PDBsum; 4A9R; -.
DR   PDBsum; 4A9S; -.
DR   PDBsum; 4A9T; -.
DR   PDBsum; 4A9U; -.
DR   PDBsum; 4BDA; -.
DR   PDBsum; 4BDB; -.
DR   PDBsum; 4BDC; -.
DR   PDBsum; 4BDD; -.
DR   PDBsum; 4BDE; -.
DR   PDBsum; 4BDF; -.
DR   PDBsum; 4BDG; -.
DR   PDBsum; 4BDH; -.
DR   PDBsum; 4BDI; -.
DR   PDBsum; 4BDJ; -.
DR   PDBsum; 4BDK; -.
DR   AlphaFoldDB; O96017; -.
DR   SMR; O96017; -.
DR   BioGRID; 116369; 209.
DR   CORUM; O96017; -.
DR   DIP; DIP-24270N; -.
DR   ELM; O96017; -.
DR   IntAct; O96017; 136.
DR   MINT; O96017; -.
DR   STRING; 9606.ENSP00000372023; -.
DR   BindingDB; O96017; -.
DR   ChEMBL; CHEMBL2527; -.
DR   DrugBank; DB06486; Enzastaurin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05149; XL844.
DR   DrugCentral; O96017; -.
DR   GuidetoPHARMACOLOGY; 1988; -.
DR   GlyGen; O96017; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O96017; -.
DR   MetOSite; O96017; -.
DR   PhosphoSitePlus; O96017; -.
DR   BioMuta; CHEK2; -.
DR   EPD; O96017; -.
DR   jPOST; O96017; -.
DR   MassIVE; O96017; -.
DR   MaxQB; O96017; -.
DR   PeptideAtlas; O96017; -.
DR   PRIDE; O96017; -.
DR   ProteomicsDB; 51198; -. [O96017-1]
DR   ProteomicsDB; 51199; -. [O96017-10]
DR   ProteomicsDB; 51200; -. [O96017-11]
DR   ProteomicsDB; 51201; -. [O96017-12]
DR   ProteomicsDB; 51202; -. [O96017-2]
DR   ProteomicsDB; 51203; -. [O96017-3]
DR   ProteomicsDB; 51204; -. [O96017-4]
DR   ProteomicsDB; 51205; -. [O96017-5]
DR   ProteomicsDB; 51206; -. [O96017-6]
DR   ProteomicsDB; 51207; -. [O96017-7]
DR   ProteomicsDB; 51208; -. [O96017-8]
DR   ProteomicsDB; 51209; -. [O96017-9]
DR   ProteomicsDB; 81589; -.
DR   ABCD; O96017; 1 sequenced antibody.
DR   Antibodypedia; 278; 2051 antibodies from 48 providers.
DR   CPTC; O96017; 2 antibodies.
DR   DNASU; 11200; -.
DR   Ensembl; ENST00000348295.7; ENSP00000329012.5; ENSG00000183765.23. [O96017-12]
DR   Ensembl; ENST00000382580.6; ENSP00000372023.2; ENSG00000183765.23. [O96017-9]
DR   Ensembl; ENST00000403642.5; ENSP00000384919.1; ENSG00000183765.23. [O96017-4]
DR   Ensembl; ENST00000404276.6; ENSP00000385747.1; ENSG00000183765.23. [O96017-1]
DR   Ensembl; ENST00000405598.5; ENSP00000386087.1; ENSG00000183765.23. [O96017-1]
DR   Ensembl; ENST00000417588.5; ENSP00000412901.1; ENSG00000183765.23. [O96017-5]
DR   Ensembl; ENST00000425190.7; ENSP00000390244.2; ENSG00000183765.23. [O96017-13]
DR   Ensembl; ENST00000433728.5; ENSP00000404400.1; ENSG00000183765.23. [O96017-8]
DR   Ensembl; ENST00000448511.5; ENSP00000404567.1; ENSG00000183765.23. [O96017-6]
DR   Ensembl; ENST00000649563.1; ENSP00000496928.1; ENSG00000183765.23. [O96017-13]
DR   Ensembl; ENST00000650281.1; ENSP00000497000.1; ENSG00000183765.23. [O96017-1]
DR   GeneID; 11200; -.
DR   KEGG; hsa:11200; -.
DR   MANE-Select; ENST00000404276.6; ENSP00000385747.1; NM_007194.4; NP_009125.1.
DR   UCSC; uc003adt.2; human. [O96017-1]
DR   CTD; 11200; -.
DR   DisGeNET; 11200; -.
DR   GeneCards; CHEK2; -.
DR   HGNC; HGNC:16627; CHEK2.
DR   HPA; ENSG00000183765; Low tissue specificity.
DR   MalaCards; CHEK2; -.
DR   MIM; 114480; phenotype.
DR   MIM; 176807; phenotype.
DR   MIM; 259500; phenotype.
DR   MIM; 604373; gene+phenotype.
DR   MIM; 609265; phenotype.
DR   neXtProt; NX_O96017; -.
DR   OpenTargets; ENSG00000183765; -.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 668; Osteosarcoma.
DR   PharmGKB; PA404; -.
DR   VEuPathDB; HostDB:ENSG00000183765; -.
DR   eggNOG; KOG0615; Eukaryota.
DR   GeneTree; ENSGT00800000124190; -.
DR   HOGENOM; CLU_070593_1_0_1; -.
DR   InParanoid; O96017; -.
DR   OMA; MLCAVQY; -.
DR   OrthoDB; 1510589at2759; -.
DR   PhylomeDB; O96017; -.
DR   TreeFam; TF101082; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O96017; -.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   SignaLink; O96017; -.
DR   SIGNOR; O96017; -.
DR   BioGRID-ORCS; 11200; 24 hits in 1116 CRISPR screens.
DR   ChiTaRS; CHEK2; human.
DR   EvolutionaryTrace; O96017; -.
DR   GeneWiki; CHEK2; -.
DR   GenomeRNAi; 11200; -.
DR   Pharos; O96017; Tchem.
DR   PRO; PR:O96017; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; O96017; protein.
DR   Bgee; ENSG00000183765; Expressed in lower esophagus mucosa and 106 other tissues.
DR   ExpressionAtlas; O96017; baseline and differential.
DR   Genevisible; O96017; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:1903926; P:cellular response to bisphenol A; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:MGI.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint signaling; TAS:UniProtKB.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0044773; P:mitotic DNA damage checkpoint signaling; IBA:GO_Central.
DR   GO; GO:0031573; P:mitotic intra-S DNA damage checkpoint signaling; IMP:UniProtKB.
DR   GO; GO:0090307; P:mitotic spindle assembly; IMP:UniProtKB.
DR   GO; GO:2000002; P:negative regulation of DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:2000210; P:positive regulation of anoikis; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0042176; P:regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0090399; P:replicative senescence; NAS:BHF-UCL.
DR   GO; GO:1903416; P:response to glycoside; IEA:Ensembl.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:MGI.
DR   GO; GO:0070242; P:thymocyte apoptotic process; IEA:Ensembl.
DR   CDD; cd00060; FHA; 1.
DR   DisProt; DP01797; -.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   Pfam; PF00498; FHA; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00240; FHA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50006; FHA_DOMAIN; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell cycle;
KW   Cell division; Disease variant; DNA damage; DNA repair;
KW   Host-virus interaction; Kinase; Li-Fraumeni syndrome; Magnesium;
KW   Metal-binding; Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor; Ubl conjugation.
FT   CHAIN           1..543
FT                   /note="Serine/threonine-protein kinase Chk2"
FT                   /id="PRO_0000085858"
FT   DOMAIN          113..175
FT                   /note="FHA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00086"
FT   DOMAIN          220..486
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..66
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          368..394
FT                   /note="T-loop/activation segment"
FT   REGION          506..538
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        7..66
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        347
FT                   /note="Proton acceptor"
FT   BINDING         227..234
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         249
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         302..308
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         351..352
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         368
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         62
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000269|PubMed:16481012"
FT   MOD_RES         68
FT                   /note="Phosphothreonine; by ATM and MAP3K20"
FT                   /evidence="ECO:0000269|PubMed:10973490,
FT                   ECO:0000269|PubMed:15342622, ECO:0000269|PubMed:16311512,
FT                   ECO:0000269|PubMed:16481012"
FT   MOD_RES         73
FT                   /note="Phosphoserine; by PLK3"
FT                   /evidence="ECO:0000269|PubMed:16481012"
FT   MOD_RES         379
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18644861"
FT   MOD_RES         383
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11390408"
FT   MOD_RES         387
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11390408"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17715138"
FT   VAR_SEQ         1..221
FT                   /note="Missing (in isoform 13)"
FT                   /evidence="ECO:0000303|PubMed:15498874"
FT                   /id="VSP_045148"
FT   VAR_SEQ         75..392
FT                   /note="Missing (in isoform 11)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014556"
FT   VAR_SEQ         107..487
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014559"
FT   VAR_SEQ         107..197
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014558"
FT   VAR_SEQ         107
FT                   /note="E -> ETESGHVTQSDLELLLSSDPPASASQSAGIRGVRHHPRPVCSLK
FT                   (in isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:15361853,
FT                   ECO:0000303|PubMed:15461802"
FT                   /id="VSP_014557"
FT   VAR_SEQ         131..147
FT                   /note="KRTDKYRTYSKKHFRIF -> EFRSYSFYLP (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014560"
FT   VAR_SEQ         148..543
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014561"
FT   VAR_SEQ         150..165
FT                   /note="VGPKNSYIAYIEDHSG -> ENLSCPYRIWFNFCLF (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014562"
FT   VAR_SEQ         166..543
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014563"
FT   VAR_SEQ         198..224
FT                   /note="VFVFFDLTVDDQSVYPKALRDEYIMSK -> EKILKIYSLSRFSKIRRGAVA
FT                   HVFNPS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10097108,
FT                   ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014564"
FT   VAR_SEQ         199..203
FT                   /note="FVFFD -> VPVER (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014565"
FT   VAR_SEQ         204..543
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014566"
FT   VAR_SEQ         228..234
FT                   /note="SGACGEV -> GRGWQIT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10097108,
FT                   ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014567"
FT   VAR_SEQ         235..543
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10097108,
FT                   ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014568"
FT   VAR_SEQ         283..289
FT                   /note="PCIIKIK -> DGRGRAV (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014569"
FT   VAR_SEQ         290..543
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014570"
FT   VAR_SEQ         337..365
FT                   /note="Missing (in isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:15361853, ECO:0000303|Ref.7"
FT                   /id="VSP_014571"
FT   VAR_SEQ         337..339
FT                   /note="YLH -> MKT (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014572"
FT   VAR_SEQ         340..543
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15361853"
FT                   /id="VSP_014573"
FT   VARIANT         17
FT                   /note="A -> S (in an osteogenic sarcoma sample; somatic
FT                   mutation; might influence susceptibility to breast cancer;
FT                   does not cause protein abrogation in familial colorectal
FT                   cancer; dbSNP:rs137853008)"
FT                   /evidence="ECO:0000269|PubMed:11746983"
FT                   /id="VAR_019101"
FT   VARIANT         59
FT                   /note="T -> K (in multiple cancers; dbSNP:rs149991239)"
FT                   /evidence="ECO:0000269|PubMed:12052256"
FT                   /id="VAR_026630"
FT   VARIANT         64
FT                   /note="E -> K (in prostate cancer; somatic mutation;
FT                   dbSNP:rs141568342)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019107"
FT   VARIANT         85
FT                   /note="P -> L (in an osteogenic sarcoma sample; neutral
FT                   allele among Ashkenazi Jewish women; dbSNP:rs17883862)"
FT                   /evidence="ECO:0000269|PubMed:11746983,
FT                   ECO:0000269|PubMed:15649950, ECO:0000269|Ref.10"
FT                   /id="VAR_019102"
FT   VARIANT         117
FT                   /note="R -> G (in BC; dbSNP:rs28909982)"
FT                   /evidence="ECO:0000269|PubMed:12454775,
FT                   ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15818573"
FT                   /id="VAR_022461"
FT   VARIANT         137
FT                   /note="R -> Q (might influence susceptibility to breast
FT                   cancer; does not cause protein abrogation in familial
FT                   colorectal cancer; dbSNP:rs368570187)"
FT                   /evidence="ECO:0000269|PubMed:12454775,
FT                   ECO:0000269|PubMed:15818573"
FT                   /id="VAR_022462"
FT   VARIANT         145
FT                   /note="R -> P (in prostate cancer; somatic mutation;
FT                   dbSNP:rs587781667)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019108"
FT   VARIANT         145
FT                   /note="R -> W (in colon cancer and LFS2; does not cause
FT                   protein abrogation in familial colorectal cancer; loss of
FT                   the ability to interact with and phosphorylate CDC25A and
FT                   to promote CDC25A degradation in response to ionizing
FT                   radiation; dbSNP:rs137853007)"
FT                   /evidence="ECO:0000269|PubMed:10617473,
FT                   ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11719428,
FT                   ECO:0000269|PubMed:12610780, ECO:0000269|PubMed:15535844,
FT                   ECO:0000269|PubMed:15818573"
FT                   /id="VAR_008554"
FT   VARIANT         157
FT                   /note="I -> T (might influence susceptibility to different
FT                   types of cancer; does not cause protein abrogation in
FT                   familial colorectal cancer; loss of the ability to interact
FT                   with and phosphorylate CDC25A and to promote CDC25A
FT                   degradation in response to ionizing radiation;
FT                   dbSNP:rs17879961)"
FT                   /evidence="ECO:0000269|PubMed:10617473,
FT                   ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:11461078,
FT                   ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:12610780,
FT                   ECO:0000269|PubMed:14612911, ECO:0000269|PubMed:15087378,
FT                   ECO:0000269|PubMed:15095295, ECO:0000269|PubMed:15239132,
FT                   ECO:0000269|PubMed:15492928, ECO:0000269|PubMed:15535844,
FT                   ECO:0000269|PubMed:15810020, ECO:0000269|PubMed:15818573,
FT                   ECO:0000269|Ref.10"
FT                   /id="VAR_008555"
FT   VARIANT         167
FT                   /note="G -> R (in prostate cancer; somatic mutation;
FT                   dbSNP:rs72552322)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019109"
FT   VARIANT         180
FT                   /note="R -> C (in prostate cancer; somatic mutation;
FT                   dbSNP:rs77130927)"
FT                   /evidence="ECO:0000269|PubMed:12533788,
FT                   ECO:0000269|PubMed:21618645"
FT                   /id="VAR_019103"
FT   VARIANT         180
FT                   /note="R -> H (in prostate cancer; somatic mutation;
FT                   dbSNP:rs137853009)"
FT                   /evidence="ECO:0000269|PubMed:12454775,
FT                   ECO:0000269|PubMed:12533788, ECO:0000269|PubMed:15818573"
FT                   /id="VAR_019110"
FT   VARIANT         181
FT                   /note="R -> C (in prostate cancer; somatic mutation;
FT                   dbSNP:rs137853010)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019104"
FT   VARIANT         181
FT                   /note="R -> H (in prostate cancer; somatic mutation;
FT                   dbSNP:rs121908701)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019105"
FT   VARIANT         239
FT                   /note="E -> K (in prostate cancer; germline mutation;
FT                   dbSNP:rs121908702)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019106"
FT   VARIANT         251
FT                   /note="I -> F (in prostate cancer; unknown pathological
FT                   significance; dbSNP:rs587780189)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019111"
FT   VARIANT         318
FT                   /note="R -> H (in prostate cancer; unknown pathological
FT                   significance; somatic mutation; dbSNP:rs143611747)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019112"
FT   VARIANT         323
FT                   /note="T -> P (in prostate cancer; somatic mutation;
FT                   dbSNP:rs750984976)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019113"
FT   VARIANT         327
FT                   /note="Y -> C (in prostate cancer; unknown pathological
FT                   significance; somatic mutation; dbSNP:rs587780194)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019114"
FT   VARIANT         347
FT                   /note="D -> N (in dbSNP:rs28909980)"
FT                   /id="VAR_029154"
FT   VARIANT         371
FT                   /note="H -> Y (confers a moderate risk of breast cancer;
FT                   partially reduces kinase activity; dbSNP:rs531398630)"
FT                   /evidence="ECO:0000269|PubMed:21618645"
FT                   /id="VAR_066012"
FT   VARIANT         390
FT                   /note="Y -> C (in BC; does not phosphorylate p53/TP53;
FT                   dbSNP:rs200928781)"
FT                   /evidence="ECO:0000269|PubMed:25619829"
FT                   /id="VAR_073020"
FT   VARIANT         406
FT                   /note="R -> H (in dbSNP:rs200649225)"
FT                   /id="VAR_024572"
FT   VARIANT         428
FT                   /note="S -> F (may increase breast cancer risk;
FT                   dbSNP:rs137853011)"
FT                   /evidence="ECO:0000269|PubMed:15649950"
FT                   /id="VAR_022463"
FT   VARIANT         436
FT                   /note="L -> M (in dbSNP:rs17882922)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021117"
FT   VARIANT         446
FT                   /note="N -> K (in dbSNP:rs17880867)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021118"
FT   VARIANT         447
FT                   /note="F -> I (in dbSNP:rs17881473)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021119"
FT   VARIANT         448
FT                   /note="I -> S (in dbSNP:rs17886163)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021120"
FT   VARIANT         476
FT                   /note="T -> K (in prostate cancer; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:12533788"
FT                   /id="VAR_019115"
FT   VARIANT         500
FT                   /note="S -> C (in dbSNP:rs28909981)"
FT                   /id="VAR_029155"
FT   VARIANT         501
FT                   /note="E -> K (in dbSNP:rs17883172)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021121"
FT   VARIANT         512
FT                   /note="L -> V (in dbSNP:rs17882942)"
FT                   /evidence="ECO:0000269|Ref.10"
FT                   /id="VAR_021122"
FT   MUTAGEN         68
FT                   /note="T->A: Loss of activation and phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11901158,
FT                   ECO:0000269|PubMed:15342622"
FT   MUTAGEN         73
FT                   /note="S->A: Impaired activation, phosphorylation by ATM
FT                   and G2/M transition checkpoint."
FT                   /evidence="ECO:0000269|PubMed:16481012"
FT   MUTAGEN         347
FT                   /note="D->A: Loss of kinase activity and of the ability to
FT                   phosphorylate CDC25A."
FT                   /evidence="ECO:0000269|PubMed:11298456,
FT                   ECO:0000269|PubMed:9836640"
FT   MUTAGEN         368
FT                   /note="D->N: Loss of autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:15342622"
FT   MUTAGEN         379
FT                   /note="S->A: Abrogates autophosphorylation at Ser-379 and
FT                   prevents ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:18644861"
FT   MUTAGEN         383
FT                   /note="T->A: Loss of phosphorylation in response to
FT                   ionizing radiation."
FT                   /evidence="ECO:0000269|PubMed:11390408"
FT   MUTAGEN         387
FT                   /note="T->A: Loss of phosphorylation in response to
FT                   ionizing radiation."
FT                   /evidence="ECO:0000269|PubMed:11390408"
FT   MUTAGEN         456
FT                   /note="S->A: Increased ubiquitination and degradation by
FT                   the proteasome."
FT                   /evidence="ECO:0000269|PubMed:17715138"
FT   STRAND          94..98
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          100..103
FT                   /evidence="ECO:0007829|PDB:3I6U"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          110..118
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   HELIX           128..132
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   HELIX           135..138
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          144..150
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          154..162
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          168..170
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          187..193
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   STRAND          197..203
FT                   /evidence="ECO:0007829|PDB:1GXC"
FT   HELIX           209..211
FT                   /evidence="ECO:0007829|PDB:3I6U"
FT   HELIX           214..219
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          220..228
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          230..239
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   TURN            240..243
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          244..251
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           253..256
FT                   /evidence="ECO:0007829|PDB:3I6U"
FT   HELIX           270..279
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          288..302
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:4BDD"
FT   HELIX           310..313
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:2W7X"
FT   HELIX           321..340
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          353..361
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          364..366
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           369..371
FT                   /evidence="ECO:0007829|PDB:4BDE"
FT   HELIX           379..385
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           388..390
FT                   /evidence="ECO:0007829|PDB:2WTJ"
FT   HELIX           393..398
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   TURN            399..403
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           407..422
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   STRAND          429..431
FT                   /evidence="ECO:0007829|PDB:2CN5"
FT   HELIX           436..442
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           449..452
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           457..466
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   TURN            471..473
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           477..481
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           484..486
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   HELIX           489..502
FT                   /evidence="ECO:0007829|PDB:2YCF"
FT   TURN            504..506
FT                   /evidence="ECO:0007829|PDB:2WTJ"
SQ   SEQUENCE   543 AA;  60915 MW;  28890ACF3C1F3408 CRC64;
     MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS QSSHSSSGTL
     SSLETVSTQE LYSIPEDQEP EDQEPEEPTP APWARLWALQ DGFANLECVN DNYWFGRDKS
     CEYCFDEPLL KRTDKYRTYS KKHFRIFREV GPKNSYIAYI EDHSGNGTFV NTELVGKGKR
     RPLNNNSEIA LSLSRNKVFV FFDLTVDDQS VYPKALRDEY IMSKTLGSGA CGEVKLAFER
     KTCKKVAIKI ISKRKFAIGS AREADPALNV ETEIEILKKL NHPCIIKIKN FFDAEDYYIV
     LELMEGGELF DKVVGNKRLK EATCKLYFYQ MLLAVQYLHE NGIIHRDLKP ENVLLSSQEE
     DCLIKITDFG HSKILGETSL MRTLCGTPTY LAPEVLVSVG TAGYNRAVDC WSLGVILFIC
     LSGYPPFSEH RTQVSLKDQI TSGKYNFIPE VWAEVSEKAL DLVKKLLVVD PKARFTTEEA
     LRHPWLQDED MKRKFQDLLS EENESTALPQ VLAQPSTSRK RPREGEAEGA ETTKRPAVCA
     AVL
//
